DE69207603D1 - Zusammensetzung und verfahren zur behandlung von zystischer fibrose - Google Patents

Zusammensetzung und verfahren zur behandlung von zystischer fibrose

Info

Publication number
DE69207603D1
DE69207603D1 DE69207603T DE69207603T DE69207603D1 DE 69207603 D1 DE69207603 D1 DE 69207603D1 DE 69207603 T DE69207603 T DE 69207603T DE 69207603 T DE69207603 T DE 69207603T DE 69207603 D1 DE69207603 D1 DE 69207603D1
Authority
DE
Germany
Prior art keywords
macromolecule
fibrose
composition
treating cystic
cystic fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69207603T
Other languages
English (en)
Other versions
DE69207603T2 (de
Inventor
Philip Felgner
Anna Abai
Marston Manthorpe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresh Tracks Therapeutics Inc
Original Assignee
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc filed Critical Vical Inc
Publication of DE69207603D1 publication Critical patent/DE69207603D1/de
Application granted granted Critical
Publication of DE69207603T2 publication Critical patent/DE69207603T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
DE69207603T 1991-08-16 1992-05-19 Zusammensetzung und verfahren zur behandlung von zystischer fibrose Expired - Fee Related DE69207603T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74590091A 1991-08-16 1991-08-16
PCT/US1992/004225 WO1993003709A1 (en) 1991-08-16 1992-05-19 Composition and method for treating cystic fibrosis

Publications (2)

Publication Number Publication Date
DE69207603D1 true DE69207603D1 (de) 1996-02-22
DE69207603T2 DE69207603T2 (de) 1996-09-12

Family

ID=24998709

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69207603T Expired - Fee Related DE69207603T2 (de) 1991-08-16 1992-05-19 Zusammensetzung und verfahren zur behandlung von zystischer fibrose

Country Status (7)

Country Link
EP (1) EP0599850B1 (de)
JP (1) JPH06510036A (de)
AT (1) ATE132742T1 (de)
AU (1) AU2143992A (de)
CA (1) CA2115364A1 (de)
DE (1) DE69207603T2 (de)
WO (1) WO1993003709A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
EP1624068A1 (de) 1993-06-01 2006-02-08 Life Technologies Inc. Genetische Impfung mit kationischen Lipidstoffen
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US6075012A (en) * 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
US5863563A (en) * 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
US5780009A (en) * 1995-01-20 1998-07-14 Nexia Biotechnologies, Inc. Direct gene transfer into the ruminant mammary gland
US5932241A (en) * 1995-06-07 1999-08-03 Valentis, Incorporated Cationic lipid DNA complexes for gene targeting
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US6258792B1 (en) 1996-04-12 2001-07-10 University Of Pittsburgh Cationic cholesteryl derivatives containing cyclic polar groups
EP0904282B1 (de) 1996-04-12 2001-12-05 University Of Pittsburgh Neue kationische cholesterin derivate mit zyklischen polaren gruppen
US6074667A (en) * 1996-11-20 2000-06-13 Kinnunen; Paavo Liposomal transfection method
US6251425B1 (en) 1998-10-02 2001-06-26 Igen, Inc. Glucoside paucilamellar vesicles
EP1129064B1 (de) 1998-11-12 2008-01-09 Invitrogen Corporation Transportreagentien
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR100927261B1 (ko) 2001-01-17 2009-11-18 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인-면역글로불린 융합 단백질
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
WO2006130034A1 (fr) 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
EP1666055A4 (de) * 2003-07-14 2010-02-10 Viktor Veniaminovich Tets Verfahren zur behandlung von onkologischen, virulenten und somatischen erkrankungen, verfahren zur kontrolle der behandlungseffizienz, pharmazeutische mittel und zusammensetzung zur durchführung dieser behandlung
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
FR2870741B1 (fr) * 2004-05-25 2008-03-14 Coletica Sa Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
SI2298815T1 (sl) 2005-07-25 2015-08-31 Emergent Product Development Seattle, Llc Zmanjšanje števila celic b z uporabo molekul, ki se specifično vežejo na cd37 in cd20
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
CA3149553C (en) 2006-06-12 2023-11-21 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
EP2486938B1 (de) 2006-09-26 2018-05-09 Infectious Disease Research Institute Impfstoffzusammensetzung mit einem synthetischen Adjuvans
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2369547T3 (es) 2006-11-28 2011-12-01 Cls Therapeutics Limited Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado del ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento.
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US7964004B2 (en) 2007-11-16 2011-06-21 Tk Energi A/S Feeding apparatus for creation of one or more plugs of compressible material for feeding into a gasifier or reactor
US9078812B2 (en) 2007-12-06 2015-07-14 The Bay Zoltan Foundation For Applied Research Particulate drug carriers as desensitizing agents
US10251839B2 (en) 2008-01-22 2019-04-09 Igi Laboratories, Inc. Lipid vesicles derived from olive oil fatty acids
EP2244694A2 (de) * 2008-01-29 2010-11-03 Shire Human Genetic Therapies, Inc. Therapeutische zusammensetzungen mit einem aminhaltigen lipid und einem protein
MX340204B (es) 2008-04-11 2016-06-30 Emergent Product Dev Seattle Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo.
CN110075113A (zh) 2008-04-17 2019-08-02 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
US9937128B2 (en) 2009-08-03 2018-04-10 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
US20140170159A9 (en) 2012-03-08 2014-06-19 Ge Wei Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
EP2858679B1 (de) 2012-06-08 2021-02-24 Translate Bio, Inc. Pulmonale verabreichung von mrns an nicht pulmonale zielzellen
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
EP2897639A4 (de) 2012-09-21 2016-05-04 Frank Bedu-Addo Verbesserte impfstoffzusammensetzungen und verfahren zur verwendung
JP6342910B2 (ja) * 2012-10-29 2018-06-13 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 遺伝子薬物療法のための新規試薬
SG11201601770YA (en) 2013-09-12 2016-04-28 Halozyme Inc Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
US20170281737A1 (en) * 2014-09-30 2017-10-05 The Medical College Of Wisconsin, Inc. Universal platform for targeting therapies to treat neurological diseases
WO2016190780A1 (en) 2015-05-22 2016-12-01 Dmitry Dmitrievich Genkin Extracellular dna as a therapeutic target in neurodegeneration
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
AU2016354590B2 (en) 2015-11-13 2023-11-23 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
CN109310773B (zh) 2016-05-16 2022-04-26 传染病研究所 含有tlr激动剂的配制品和使用方法
AU2017273650B2 (en) 2016-06-01 2022-08-18 Access To Advanced Health Institute Nanoalum particles containing a sizing agent
US11878060B2 (en) 2016-08-07 2024-01-23 Novartis Ag mRNA-mediated immunization methods
EP3538073A1 (de) * 2016-11-10 2019-09-18 Translate Bio, Inc. Verbessertes verfahren zur herstellung von mrna-beladenen lipidnanopartikeln
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
CA3073211A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
EP3461487A1 (de) 2017-09-29 2019-04-03 Nlife Therapeutics S.L. Zusammensetzungen und verfahren zur abgabe von mrna an leberzellen
CN112292453A (zh) 2018-01-16 2021-01-29 Cls治疗有限公司 通过肝脏表达具有脱氧核糖核酸酶（dna酶）活性的酶治疗疾病
AU2019333042A1 (en) 2018-08-29 2021-03-04 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE69032284T2 (de) * 1989-03-21 1998-10-08 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
ES2210224T3 (es) * 1989-08-22 2004-07-01 Hsc Research Development Corporation Gen de la fibrosis quistica.

Also Published As

Publication number Publication date
ATE132742T1 (de) 1996-01-15
JPH06510036A (ja) 1994-11-10
WO1993003709A1 (en) 1993-03-04
AU2143992A (en) 1993-03-16
EP0599850B1 (de) 1996-01-10
CA2115364A1 (en) 1993-03-04
DE69207603T2 (de) 1996-09-12
EP0599850A1 (de) 1994-06-08

Similar Documents

Publication Publication Date Title
DE69207603T2 (de) Zusammensetzung und verfahren zur behandlung von zystischer fibrose
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
DE69830185D1 (de) Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
DE69636764D1 (de) Zusammensetzungen zur behandlung von ischamischem gewebe
ATE248586T1 (de) Sphingosome mit verbesserter arzneistoffabgage
ATE99949T1 (de) Natuerliches oberflaechenwirksames lungenpraeparat, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen.
ATE132040T1 (de) Verwendung von phospholipiden zur herstellung eines topischen arzneimittels zur beinflussung des serumcholesterinspiegels
DE68924537D1 (de) Zusammensetzung zur behandlung der symptome verursacht durch beseitigung von tabak.
DE69822496D1 (de) Lipidkomplex-lyophilisat von wasserunlöslichen porphyrinen
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
DK0661987T3 (da) Morphogeninduceret leverregeneration
ATE172117T1 (de) Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69129747T2 (de) In lösung bringen von proteinen in aktiver form
ATE117898T1 (de) Verfahren und mittel zur präventiven behandlung von chirurgischen adhäsionen.
DK325289A (da) Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
RU96106437A (ru) Способ лечения сухой остаточной полости после перенесенного абсцесса легкого
JPH0662428B2 (ja) 創傷治癒を促進する調製物の製造方法
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
RU97107684A (ru) Способ лечения пузырчатки
RU94015015A (ru) Способ лечения туберкулеза легких

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee